Literature DB >> 2173261

Sequence analyses of the 3' genome end and NP gene of human parainfluenza type 2 virus: sequence variation of the gene-starting signal and the conserved 3' end.

T Yuasa1, H Bando, M Kawano, M Tsurudome, M Nishio, K Kondo, H Komada, Y Ito.   

Abstract

We cloned and determined the nucleotide sequences of cDNAs against nucleocapsid protein (NP) mRNA and the genomic RNA of human parainfluenza type 2 virus (PIV-2). The 3' terminal region of genomic RNA was compared among PIV-2, mumps virus (MuV), Newcastle disease virus (NDV), measles virus (MV), PIV-3, bovine parainfluenza type 3 virus (BPIV-3), Sendai virus (SV), and vesicular stomatitis virus (VSV), and an extensive sequence homology was observed between PIV-2 and MuV. Although no significant sequence relatedness was observed between PIV-2 and other viruses, the terminal four nucleotides were identical in the viruses compared, implying a specific role of these nucleotides on the replication of paramyxoviruses. A primer extension analysis elucidated the major NP mRNA initiation site with the sequence UCUAAGCC, which showed a moderate homology with the gene-starting consensus sequences of other paramyxoviruses. On the other hand, the NP mRNA was terminated at the nucleotide stretch AAAUUCUUUUU, and this sequence was conserved in all the PIV-2 genes, indicating that the oligonucleotides will form a part of the gene attenuation signal of PIV-2. Comparisons of NP protein sequence indicated a possible subgrouping of the paramyxoviruses into two groups, one of which is a group including PIV-2, PIV-4, MuV, and NDV, and another is a group including PIV-3, BPIV-3, and SV. This result supports an idea from our previous studies using polyclonal and monoclonal antibodies. Furthermore, our data indicated that the PIV-2 NP protein sequence was more closely related to MV and CDV than to other parainfluenza viruses, PIV-3 and SV.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2173261     DOI: 10.1016/0042-6822(90)90145-h

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  Characterizations of the human parainfluenza type 2 virus gene encoding the L protein and the intergenic sequences.

Authors:  M Kawano; K Okamoto; H Bando; K Kondo; M Tsurudome; H Komada; M Nishio; Y Ito
Journal:  Nucleic Acids Res       Date:  1991-05-25       Impact factor: 16.971

2.  The hypervariable C-terminal tail of the Sendai paramyxovirus nucleocapsid protein is required for template function but not for RNA encapsidation.

Authors:  J Curran; H Homann; C Buchholz; S Rochat; W Neubert; D Kolakofsky
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

3.  Molecular evolution of human paramyxoviruses. Nucleotide sequence analyses of the human parainfluenza type 1 virus NP and M protein genes and construction of phylogenetic trees for all the human paramyxoviruses.

Authors:  K Miyahara; S Kitada; M Yoshimoto; H Matsumura; M Kawano; H Komada; M Tsurudome; S Kusagawa; M Nishio; Y Ito
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

4.  RNA replication for the paramyxovirus simian virus 5 requires an internal repeated (CGNNNN) sequence motif.

Authors:  S K Murphy; G D Parks
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

5.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1991-07-11       Impact factor: 16.971

6.  Legume lectins inhibit human parainfluenza virus type 2 infection by interfering with the entry.

Authors:  Jun Uematsu; Aoi Koyama; Sayaka Takano; Yukari Ura; Miho Tanemura; Sahoko Kihira; Hidetaka Yamamoto; Mitsuo Kawano; Masato Tsurudome; Myles O'Brien; Hiroshi Komada
Journal:  Viruses       Date:  2012-06-29       Impact factor: 5.048

7.  Validation of a multiplex reverse transcriptase PCR ELISA for the detection of 19 respiratory tract pathogens.

Authors:  W Puppe; J Weigl; B Gröndahl; M Knuf; S Rockahr; P von Bismarck; G Aron; H G M Niesters; A D M E Osterhaus; H-J Schmitt
Journal:  Infection       Date:  2012-07-31       Impact factor: 3.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.